- Conditions
- Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
- Interventions
- Apixaban, Placebo
- Drug
- Lead sponsor
- Nirmish Shah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 841–864
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Partial-thickness Burn Wounds
- Interventions
- Intact fish skin graft, autograft
- Device · Procedure
- Lead sponsor
- Kerecis Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Chronic Obstructive Pulmonary Disease, Alpha-1 Antitrypsin Deficiency
- Interventions
- six-minute walk study indoors, six-minute walk study outdoors
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Hyperinsulinemia Hypoglycemia
- Interventions
- Exendin (9-39)
- Drug
- Lead sponsor
- Tracey McLaughlin
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 99 Years
- Enrollment
- 1,310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 47
- States / cities
- Anchorage, Alaska • Little Rock, Arkansas • Long Beach, California + 41 more
- Conditions
- Cystic Fibrosis
- Interventions
- 7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
- Drug
- Lead sponsor
- University of Washington, the Collaborative Health Studies Coordinating Center
- Other
- Eligibility
- 3 Years to 5 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
- Conditions
- Fluid Loss, Symptom Complex, Triple, Emergencies
- Interventions
- Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
- Drug
- Lead sponsor
- Nicholas M Mohr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Transdiagnostic Behavioral Sleep Intervention
- Behavioral
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Gaucher Disease
- Interventions
- Eliglustat tartrate
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- San Diego, California • New Haven, Connecticut • Decatur, Georgia + 6 more
- Conditions
- Huntington Disease, Chorea
- Interventions
- Risperidone, BioStamp nPoint device
- Drug · Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- HIV Infections, Lipodystrophy
- Interventions
- Pravastatin sodium, Fenofibrate
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 630 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2003
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 33 more
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- methadone hydrochloride, morphine sulfate, oxycodone hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 2
- States / cities
- Spartanburg, South Carolina • Houston, Texas
- Conditions
- Parenteral Nutrition, Necrotizing Enterocolitis, Digestive System Abnormalities, Cholestasis
- Interventions
- Remove Mn from PN if evidence of increased brain Mn on MRI
- Dietary Supplement
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 30 Days to 6 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Covid19, Androgen Receptor Gene Overexpression
- Interventions
- COVID-19 Androgen Sensitivity Test (CoVAST)
- Genetic
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Irvine, California
- Conditions
- Duchenne Muscular Dystrophy (DMD)
- Interventions
- SGLT-2 inhibitor, SGLT2 inhibitor
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 8 Years to 18 Years · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Locally Advanced or Metastatic Cancers, Metastatic Human Papillomavirus-Related Malignant Neoplasm
- Interventions
- TST005
- Drug
- Lead sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Dallas, Texas • San Antonio, Texas
- Conditions
- Sjögren Syndrome, Dry Eye
- Interventions
- observational study
- Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 12 more
- Conditions
- Pectus Excavatum
- Interventions
- Epidural, PCA
- Other
- Lead sponsor
- Children's Mercy Hospital Kansas City
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Kansas City, Missouri
- Conditions
- Fanconi's Anemia
- Interventions
- anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, fludarabine, methylprednisolone
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 0 Years to 34 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Rotator Cuff Tears, Shoulder Injuries, Hallux Valgus, Ankle Arthropathy, Clavicle Fracture
- Interventions
- Experimental Treatment, Sham Comparator
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Prematurity, Symptomatic Respiratory Disease, Bronchopulmonary Dysplasia
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Up to 7 Days
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Rochester, New York
- Conditions
- Atopic Dermatitis
- Interventions
- Pimecrolimus Cream, 1%, Elidel® (pimecrolimus) Cream, Placebo of Pimecrolimus Cream, 1%
- Drug
- Lead sponsor
- Glenmark Pharmaceuticals Ltd. India
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 755 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 27
- States / cities
- Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more
- Conditions
- Classic Galactosemia
- Interventions
- AT-007, Placebo
- Drug · Other
- Lead sponsor
- Applied Therapeutics, Inc.
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Ann Arbor, Michigan